The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.

Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.

Provided is a composition for promoting secretion of extracellular vesicles, which comprises a compound having a structure of the formula I (wherein each substituent is as defined in the specification), a racemate thereof or a stereoisomer thereof, or a salt thereof, or a compound having a structure of the formula II (wherein each substituent is as defined in the specification), or a stereoisomer thereof, or a salt thereof, or, cucurbitacin, or a stereoisomer thereof, or a salt thereof.

Compounds that can be used to increase NAD levels are described by inhibiting NAD+ degrading enzymes such as CD38 are described. The compounds have a structure according to formula I or Formula II, as described herein, or pharmaceutically acceptable salts thereof, wherein the attached groups are as defined in the specification. Methods of increasing intracellular NAD+ levels in a subject by administering an effective amount of a compound according to formula I or formula II to the subject are also described.

Compounds that can be used to increase NAD levels are described by inhibiting NAD+ degrading enzymes such as CD38 are described. The compounds have a structure according to formula I or Formula II, as described herein, or pharmaceutically acceptable salts thereof, wherein the attached groups are as defined in the specification. Methods of increasing intracellular NAD+ levels in a subject by administering an effective amount of a compound according to formula I or formula II to the subject are also described.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.